Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
side by side viewer icon HTML

Abstract

Objective

This study aimed to determine the relationship between Radiation-Induced Lung Injury (RILI) and the clinical outcome of Non-Small Cell Lung Cancer (NSCLC) following Stereotactic Ablative Radiotherapy (SABR).

Methods

Clinical data and follow-up CT scanning of 101 patients with early NSCLC who received SABR treatment from January 2012 to December 2018 were retrospectively collected, and the Progression Free Survival (PFS) was calculated. CT features of peritumoral RILI were observed by 3 radiologists, each with 10 to 15 years of experience, based on consensus among 3 radiologists and divided into 3 types. Type 1: Diffuse consolidation surrounding the tumor, including the tumor boundary. Type 2: Ground Glass Opacities (GGOs) covering more than 180 degrees around the tumor. Type 3: GGOs surrounding the tumor but covering less than 180 degrees. Log-rank test was used to analyze the correlation between the classification of radiation-induced lung injury CT findings and PFS. Independent predictors of PFS rate were analyzed by COX multivariate regression.

Results

The 5-year PFS rates based on RILI types observed at 6-8 months post-SABR were: Type 1 = 69.5%, Type 2 = 50.9%, and Type 3 = 36.1%. A statistically significant difference was observed among the three RILI types (p=0.025). COX multivariate regression analysis showed that RILI were independent factors influencing PFS (at 6-8 months follow-up after radiotherapy (p=0.041).

Conclusion

Patients with more extensive and denser RILI tend to have a longer PFS. Data from our cohort study indicate that the 6- 8 months post-SABR period represents the optimal follow-up window, as evidenced by significant progression-free survival rate dynamics during this interval (HR = 1.5, 95% CI 1.0-2.2, p < 0.05).

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056388161250320055401
2025-04-09
2026-01-11

  • From This Site

    /content/journals/cmir/10.2174/0115734056388161250320055401
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056388161.html?itemId=/content/journals/cmir/10.2174/0115734056388161250320055401&mimeType=html&fmt=ahah

References

  1. BrayF. LaversanneM. SungH. FerlayJ. SiegelR.L. SoerjomataramI. JemalA. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202474322926310.3322/caac.2183438572751
     [Google Scholar]
  2. ZhangW. LinX. LiX. WangM. SunW. HanX. SunD. Survival prediction model for non-small cell lung cancer based on somatic mutations.J. Gene Med.2020229e320610.1002/jgm.320632367667
     [Google Scholar]
  3. StanicS. PaulusR. TimmermanR.D. MichalskiJ.M. BarrigerR.B. BezjakA. VideticG.M.M. BradleyJ. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: An analysis of RTOG 0236.Int. J. Radiat. Oncol. Biol. Phys.20148851092109910.1016/j.ijrobp.2013.12.05024661663
     [Google Scholar]
  4. ZhengX. SchipperM. KidwellK. LinJ. ReddyR. RenY. ChangA. LvF. OrringerM. Spring KongF.M. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis.Int. J. Radiat. Oncol. Biol. Phys.201490360361110.1016/j.ijrobp.2014.05.05525052562
     [Google Scholar]
  5. MaL. XiangJ. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis.Thorac. Cancer20167444245110.1111/1759‑7714.1235227385987
     [Google Scholar]
  6. SahaA. BeasleyM. HattonN. DickinsonP. FranksK. ClarkeK. JainP. TeoM. MurrayP. LilleyJ. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) – An analysis of UK’s largest cohort of lung SABR patients.Radiother. Oncol.202115615315910.1016/j.radonc.2020.12.01533333139
     [Google Scholar]
  7. LeeP. LooB.W.Jr BiswasT. DingG.X. El NaqaI.M. JacksonA. KongF.M. LaCoutureT. MiftenM. SolbergT. TomeW.A. TaiA. YorkeE. LiX.A. Local control after stereotactic body radiation therapy for stage I non-small cell lung cancer.Int. J. Radiat. Oncol. Biol. Phys.2021110116017110.1016/j.ijrobp.2019.03.04530954520
     [Google Scholar]
  8. ChangJ.Y. MehranR.J. FengL. VermaV. LiaoZ. WelshJ.W. LinS.H. O’ReillyM.S. JeterM.D. BalterP.A. McRaeS.E. BerryD. HeymachJ.V. RothJ.A. AntonoffM. HofstetterW. RajaramR. RiceD. SepesiB. SwisherS. VaporciyanA. WalshG. DeGraafC. CorreaA. ChenA. GandhiS. KomakiR. LeeP. NguyenQ-N. NingM. GaoS. Pollard-LarkinJ. NitschP. SadagopanR. WangX. STARS Lung Cancer Trials Group Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery.Lancet Oncol.202122101448145710.1016/S1470‑2045(21)00401‑034529930
     [Google Scholar]
  9. KannB.H. VermaV. StahlJ.M. RossR. DosoretzA.P. ShafmanT.D. GrossC.P. ParkH.S. YuJ.B. DeckerR.H. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.Radiother. Oncol.2019134444910.1016/j.radonc.2019.01.02731005223
     [Google Scholar]
  10. LaesekeP. NgC. FerkoN. NaghiA. WrightG.W.J. ZhangY. LaidlawA. KalsekarI. LaxmananB. GhoshS.K. ZhouM. SzaparyP. PritchettM. Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis.Lung Cancer202318210725910.1016/j.lungcan.2023.10725937321074
     [Google Scholar]
  11. YangH. WangL. ShaoG. DongB. WangF. WeiY. LiP. ChenH. ChenW. ZhengY. HeY. ZhaoY. DuX. SunX. WangZ. WangY. ZhouX. LaiX. FengW. ShenL. QiuG. JiY. ChenJ. JiangY. LiuJ. ZengJ. WangC. ZhaoQ. YangX. HuX. MaH. ChenQ. ChenM. JiangH. XuY. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.Front. Oncol.20221296736010.3389/fonc.2022.96736035982975
     [Google Scholar]
  12. TianS. SwitchenkoJ.M. BuchwaldZ.S. PatelP.R. SheltonJ.W. KahnS.E. PillaiR.N. SteuerC.E. OwonikokoT.K. BeheraM. CurranW.J. HigginsK.A. Lung stereotactic body radiation therapy and concurrent immunotherapy: A multicenter safety and toxicity analysis.Int. J. Radiat. Oncol. Biol. Phys.2020108130431310.1016/j.ijrobp.2019.12.03031982496
     [Google Scholar]
  13. TimmermanRD HuC MichalskiJ StraubeW GalvinJ JohnstoneD BradleyJ BarrigerR BezjakA VideticGM Long-term results of RTOG 0236: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage i non-small cell lung cancer.Int. J. Radiat. Oncol. Biol. Phys.2014901S3010.1016/j.ijrobp.2014.05.135
     [Google Scholar]
  14. YangY. LiG. LiS. WangY. ZhaoY. DongB. WangJ. ZhuR. ChenM. CT appearance pattern after stereotactic body radiation therapy predicts outcomes in early-stage non-small-cell lung cancer.Front. Oncol.20211174678510.3389/fonc.2021.74678534707992
     [Google Scholar]
  15. RondenM.I. PalmaD. SlotmanB.J. SenanS. Advanced Radiation Technology Committee of the International Association for the Study of Lung Cancer Brief report on radiological changes following stereotactic ablative radiotherapy (SABR) for early-stage lung tumors: A pictorial essay.J. Thorac. Oncol.201813685586210.1016/j.jtho.2018.02.02329518554
     [Google Scholar]
  16. AzzamE.I. Jay-GerinJ.P. PainD. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury.Cancer Lett.20123271-2486010.1016/j.canlet.2011.12.01222182453
     [Google Scholar]
  17. KuipersM.E. van Doorn-WinkK.C.J. HiemstraP.S. SlatsA.M. Predicting radiation-induced lung injury in patients with lung cancer: Challenges and opportunities.Int. J. Radiat. Oncol. Biol. Phys.2024118363964910.1016/j.ijrobp.2023.10.04437924986
     [Google Scholar]
  18. SoysouvanhF. BenadjaoudM.A. Dos SantosM. MondiniM. LavigneJ. BerthoA. BuardV. TarletG. AdnotS. DeutschE. GuipaudO. PagetV. FrançoisA. MilliatF. Stereotactic lung irradiation in mice promotes long-term senescence and lung injury.Int. J. Radiat. Oncol. Biol. Phys.202010651017102710.1016/j.ijrobp.2019.12.03931987976
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056388161250320055401
Loading
Radiation-induced Lung Injury CT Features: Early Non-Small Cell Lung Cancer SBRT Prognosticators
Curr. Med. Imaging 21, E15734056388161 (2025); https://doi.org/10.2174/0115734056388161250320055401
/content/journals/cmir/10.2174/0115734056388161250320055401
/content/journals/cmir/10.2174/0115734056388161250320055401
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Ground Glass Opacities; Non-small cell lung cancer; Progression Free Survival; Progression free survival.; Radiation-induced lung injuries; Stereotactic ablative radiotherapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test